Abbvie Inc. ABBV

Revenue Intelligence Report • 58 quarters of SEC filing data • Updated 2026-10-14 • Data through 2026-06-30

Abbvie Inc.'s latest quarterly revenue is $17.0B for the period ending 2026-06-30. The model projects $66.9B across the next four quarters (+4.0% versus the preceding four quarters). The forecast uses SG&A data; model selection and estimation exclude the latest quarter, whose retrospective holdout error is 9.1%. These are statistical associations, not estimates of the causal effect of spending.

Investment Thesis

The GAM forecast is based on reported revenue and SG&A data through 2026-06-30. Training MAPE measures fit to historical data; the separately reported holdout error measures a withheld quarter. Spending coefficients describe associations and do not establish causation.

Next 4 Quarters
$66.9B
+4.0% YoY
SG&A Elasticity
0.83x
Training Fit
4.5% MAPE
Retrospective holdout (Q2 FY2026): The model predicted $15.45B vs the actual $16.99B — an error of 9.1%.
Retrospective one-quarter holdout: model fitting and selection exclude this quarter. Historical inputs use the latest available restatements, so this is not a preserved real-time forecast.
Note: Abbvie Inc. does not report R&D expenses separately. The model uses the available expense measure without a separate R&D term.

Revenue Forecast

ABBV Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q2 FY2026
Period end 2026-06-30		 $15.45B $16.99B $13.10B–$18.22B +0.2% ✓ In range
Q3 FY2026
Period end 2026-09-30		 $16.28B $13.55B–$19.56B +3.2%
Q4 FY2026
Period end 2026-12-31		 $17.14B $13.91B–$21.12B +3.2%
Q1 FY2027
Period end 2027-03-31		 $16.97B $13.40B–$21.51B +13.1%
Q2 FY2027
Period end 2027-06-30		 $16.55B $12.63B–$21.68B -2.6%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Abbvie Inc.'s systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Jan–Mar) 0.949 -5.1% -5.1% below trend 15
FQ2 (Apr–Jun) 1.0046 +0.5% In line with trend 14
FQ3 (Jul–Sep) 1.0085 +0.9% In line with trend 14
FQ4 (Oct–Dec) 1.0481 +4.8% +4.8% above trend 14

Spending and Revenue

ABBV Spending Timing
Reading this chart: Each line shows the cumulative revenue association with a 1% change in spending over subsequent quarters. These estimates describe historical associations and do not establish causation.

Time-Varying Spending Associations

Time-varying analysis: A penalized spline model (GAM) tracks the association between log spending and log revenue over 58 quarters. Its coefficients describe conditional historical associations, not causal returns on spending.
Current SG&A elasticity: 0.3477x
The model-term chart shows relative absolute term magnitudes. Its percentages are not shares of revenue or causal contributions to growth.
Enhanced forecast: The time-varying model (GAM) was selected using training fit, before evaluating the withheld quarter. Its holdout error is -9.1%.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. SEC source data. Forecast model: GAM; spending associations: ARDL (log-log) with 58 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

COO DXCM VTRS MRK COR DHR CAH A